Ceritinib cost effective for ALK-positive advanced NSCLC in China

PharmacoEconomics & Outcomes News Weekly - 2020

Tóm tắt

Từ khóa


Tài liệu tham khảo

Li H, et al. Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer. Clinical Drug Investigation : 9 Dec 2019. Available from: URL: https://doi.org/10.1007/s40261-019-00880-8

Thông tin
Thông tin xuất bản

PharmacoEconomics & Outcomes News Weekly

Thông tin tác giả